Editorial Volume 9 Issue 4
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand
Received: December 19, 2022 | Published: December 23, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Differences in levels of plasma, salivary, and nasal antibody to SARS-CoV-2 (Covid-19) after Covid-19 vaccination and during natural infection. J Lung Pulm Respir Res. 2022;9(4):100. DOI: 10.15406/jlprr.2022.09.00288
Cellular or antibody responses is measured in the most studies of immunity to SARS-CoV-2 (COVID-19).1 Nevertheless, if ever SARS-CoV-2 (COVID-19) present in the plasma, the infectious virus is rarely infects the nasal and conjunctival mucosal surfaces.1 In COVID-19-infected-unvaccinated and unvaccinated-COVID-19-uninfected individuals, the levels of nasal and salivary anti-spike antibody correlated significantly with plasma antibody.1,2 The reported mean correlations for titers in plasma and saliva for IgG and IgA were moderate (p = 0.55; 95 % CI : 0.38-9.73) and weak (p = 0.28; 95 % CI : 0.12-0.44), respectively.2 A previous systematic review demonstrated that previous-COVID-19-infected-vaccinated individuals demonstrated boosting anti-spike antibody levels in the nose or saliva less than in plasma.1
In conclusion, potent immune response induced by COVID-19 mucosal vaccines at the sites of SARS-CoV-2 (COVID-19) infection is urgently needed. Persistent mucosal antibody may not indicate persistent increase of SARS-CoV-2 plasma antibody levels.
None.
There are no conflicting interests declared by the authors.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
November is observed as Lung Cancer Awareness Month, dedicated to raising
awareness, encouraging early detection, and supporting advances in lung cancer prevention, diagnosis, and treatment.
Researchers and healthcare professionals play an important role in this effort by promoting evidence-based practices
and improving patient care and outcomes.
In recognition of this initiative, the Journal of Lung, Pulmonary and Respiratory Research (JLPRR) is offering a 40%
reduction in the Article Processing Charge (APC) for manuscripts received on or before November 30, 2026
.